Innoviva Quick Ratio 2010-2023 | INVA
Historical quick ratio values for Innoviva (INVA) over the last 10 years.
| Innoviva Quick Ratio Historical Data |
| Date |
Current Assets - Inventory |
Current Liabilities |
Quick Ratio |
| 2023-12-31 |
$0.30B |
$0.04B |
7.96 |
| 2023-09-30 |
$0.26B |
$0.04B |
7.31 |
| 2023-06-30 |
$0.28B |
$0.04B |
7.02 |
| 2023-03-31 |
$0.25B |
$0.04B |
6.47 |
| 2022-12-31 |
$0.39B |
$0.14B |
2.87 |
| 2022-09-30 |
$0.38B |
$0.16B |
2.34 |
| 2022-06-30 |
$0.00B |
$0.13B |
0.00 |
| 2022-03-31 |
$0.00B |
$0.11B |
0.00 |
| 2021-12-31 |
$0.00B |
$0.01B |
0.00 |
| 2021-09-30 |
$0.00B |
$0.00B |
0.00 |
| 2021-06-30 |
$0.00B |
$0.01B |
0.00 |
| 2021-03-31 |
$0.00B |
$0.00B |
0.00 |
| 2020-12-31 |
$0.00B |
$0.01B |
0.00 |
| 2020-09-30 |
$0.00B |
$0.00B |
0.00 |
| 2020-06-30 |
$0.00B |
$0.01B |
0.00 |
| 2020-03-31 |
$0.00B |
$0.00B |
0.00 |
| 2019-12-31 |
$0.00B |
$0.01B |
0.00 |
| 2019-09-30 |
$0.00B |
$0.00B |
0.00 |
| 2019-06-30 |
$0.00B |
$0.01B |
0.00 |
| 2019-03-31 |
$0.00B |
$0.00B |
0.00 |
| 2018-12-31 |
$0.00B |
$0.01B |
0.00 |
| 2018-09-30 |
$0.00B |
$0.00B |
0.00 |
| 2018-06-30 |
$0.00B |
$0.01B |
0.00 |
| 2018-03-31 |
$0.00B |
$0.00B |
0.00 |
| 2017-12-31 |
$0.00B |
$0.04B |
0.00 |
| 2017-09-30 |
$0.00B |
$0.03B |
0.00 |
| 2017-06-30 |
$0.00B |
$0.03B |
0.00 |
| 2017-03-31 |
$0.00B |
$0.02B |
0.00 |
| 2016-12-31 |
$0.00B |
$0.02B |
0.00 |
| 2016-09-30 |
$0.00B |
$0.02B |
0.00 |
| 2016-06-30 |
$0.00B |
$0.02B |
0.00 |
| 2016-03-31 |
$0.00B |
$0.01B |
0.00 |
| 2015-12-31 |
$0.00B |
$0.01B |
0.00 |
| 2015-09-30 |
$0.00B |
$0.01B |
0.00 |
| 2015-06-30 |
$0.00B |
$0.01B |
0.00 |
| 2015-03-31 |
$0.00B |
$0.01B |
0.00 |
| 2014-12-31 |
$0.00B |
$0.01B |
0.00 |
| 2014-09-30 |
$0.00B |
$0.04B |
0.00 |
| 2014-06-30 |
$0.00B |
$0.05B |
0.00 |
| 2014-03-31 |
$0.38B |
$0.04B |
8.57 |
| 2013-12-31 |
$0.47B |
$0.08B |
5.60 |
| 2013-09-30 |
$0.51B |
$0.04B |
13.28 |
| 2013-06-30 |
$0.45B |
$0.04B |
11.62 |
| 2013-03-31 |
$0.47B |
$0.03B |
15.83 |
| 2012-12-31 |
$0.25B |
$0.03B |
8.46 |
| 2012-09-30 |
$0.28B |
$0.03B |
10.24 |
| 2012-06-30 |
$0.30B |
$0.03B |
11.60 |
| 2012-03-31 |
$0.00B |
$0.03B |
0.00 |
| 2011-12-31 |
$0.00B |
$0.05B |
0.00 |
| 2011-09-30 |
$0.00B |
$0.04B |
0.00 |
| 2011-06-30 |
$0.00B |
$0.04B |
0.00 |
| 2011-03-31 |
$0.00B |
$0.03B |
0.00 |
| 2010-12-31 |
$0.00B |
$0.04B |
0.00 |
| 2010-09-30 |
$0.00B |
$0.04B |
0.00 |
| 2010-06-30 |
$0.00B |
$0.04B |
0.00 |
| 2010-03-31 |
$0.00B |
$0.04B |
0.00 |
| 2009-12-31 |
$0.00B |
$0.04B |
0.00 |
| 2009-09-30 |
$0.00B |
$0.04B |
0.00 |
| 2009-06-30 |
$0.00B |
$0.04B |
0.00 |
| 2009-03-31 |
$0.00B |
$0.04B |
0.00 |
| Sector |
Industry |
Market Cap |
Revenue |
| Medical |
Large Cap Pharmaceutical |
$0.965B |
$0.310B |
|
Innoviva, Inc. is focused on the development, commercialization and financial management of bio-pharmaceuticals. The company's portfolio of respiratory assets partnered with Glaxo Group Limited, including RELVAR(R)/BREO(R) ELLIPTA(R) and ANORO(R) ELLIPTA(R). Innoviva, Inc., formerly known as Theravance, Inc., is headquartered in South San Francisco, California.
|
